Biohit Launches New Electronic Pipette for Precise Dispensing in Small Volumes
|| Print ||
|Monday, 20 June 2011 15:00 (UTC + 2)|
Helsinki, Finland, June 20, 2011 / B3C newswire / - Biotechnology company Biohit has developed a new electronic pipette especially suitable for dispensing small volumes of liquid. Thanks to the patented technology of the pipette, the liquid is dispensed from the pipette tip very rapidly, which ensures that the tip is completely emptied. Thus there will not be the usual drop of liquid left at the tip and no need to touch the receiving vessel wall during pipetting. As a result, the handling of the liquid is contamination free, more precise and faster than with other pipettes.
Biohit will launch the pipette under the commercial name eLINE 0.1 – 5 µl and it will be available globally as of June 27th 2011. The pipette is suitable for handling 0.1 – 5 micro litres of liquid and is targeted especially for molecular biology laboratories. The new pipette complements Biohit’s range of single channel pipettes.
Biohit has the world’s largest range of single and multichannel pipettes and the company is the market leader in electronic pipettes. Biohit also manufactures pipettes to many leading brand owners as an OEM partner. In 2010, over 90% of Biohit’s net sales of MEUR 40 were generated by pipettes and connected products and services.
Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective liquid handling solutions for laboratory work as well as diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract. The end users of Biohit’s products are e.g. the pharmaceutical industry, the food industry, research institutes and universities as well as the public and private healthcare sectors.
Biohit has two business segments: Liquid Handling and Diagnostics. Liquid Handling products include electronic and mechanical pipettes, disposable tips as well as pipette maintenance and calibration services. The Diagnostics business comprises products and analysis systems for the early diagnosis and prevention of gastrointestinal diseases, such as the blood-sample based GastroPanel examination for the diagnosis of stomach illnesses and associated risks, and Acetium capsules, which bind carcinogenic acetaldehyde in the stomach.
In 2010, Biohit’s net sales were MEUR 40 and the company employed approximately 400 people. Biohit is headquartered in Helsinki, Finland, and has production facilities in Helsinki, Kajaani and in Shanghai, China. It has subsidiaries in France, Germany, the UK, Russia, India, China, Japan and the USA. The company also has a representative office in Singapore. Biohit's products are also sold through about 200 distributors in 70 countries.
Biohit's Series B share is quoted on NASDAQ OMX Helsinki in the Small Cap/Healthcare group and is traded under the code BIOBV.
More information: www.biohit.com.